Key result
Dexmedetomidine significantly reduced the overall incidence of ventricular arrhythmias in adult patients during the perioperative cardiac surgery period (RR 0.35; 95% CI 0.16-0.76).
Why the study?
The study was conducted to assess the antiarrhythmic properties of dexmedetomidine in patients in the intensive care unit.
Does dexmedetomidine reduce the incidence of ventricular arrhythmias in critically ill patients during the perioperative cardiac surgery period?
Meta-Analysis
Does dexmedetomidine reduce the incidence of ventricular arrhythmias in critically ill patients during the perioperative cardiac surgery period?
Relative Risk: 0.35 (95% CI 0.16–0.76)
Dexmedetomidine reduces the incidence of ventricular arrhythmias, particularly ventricular tachycardia, in critically ill patients during the perioperative cardiac surgery period, though it increases the risk of bradycardia.
Supports dexmedetomidine consideration perioperatively in cardiac surgery; extends RCT evidence for ventricular arrhythmia prevention.
Purpose. To assess the antiarrhythmic properties of dexmedetomidine in patients in the intensive care unit. Methods. A literature review was conducted with Ovid MEDLINE (R), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Embase, and Scopus. Study Selection. Randomized controlled trials were included, examining the incidence of ventricular arrhythmias, ventricular tachycardia, or ventricular fibrillation with dexmedetomidine compared to placebo or an alternative sedative agent. For each publication that met the selection criteria, the patient demographics, incidence of arrhythmias, mortality, and adverse events were collected. Data extraction was carried out by two authors independently. Results. We identified 6 out of 126 studies that met the selection criteria for our meta-analysis, all of which focused on the perioperative cardiac surgery period. Patients receiving dexmedetomidine demonstrated a significant reduction of the overall incidence of ventricular arrhythmias (RR 0.35, 95% CI 0.16, 0.76). In particular, dexmedetomidine significantly decreased the risk of ventricular tachycardia compared with control (RR 0.25, 95% CI 0.08, 0.80, I2 0%). Regarding adverse events, dexmedetomidine significantly increased the frequency of bradycardia (RR 2.78 95% CI 2.00, 3.87). However, there was no significant difference in mortality (RR 0.59 95% CI 0.12, 3.02). Conclusion. From this meta-analysis, we report a decreased incidence of ventricular tachycardia with dexmedetomidine in critically ill patients. This result favors the use of dexmedetomidine for its antiarrhythmic properties.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2022) conducted a meta-analysis in Ventricular arrhythmias in intensive care / perioperative cardiac surgery. Dexmedetomidine vs. Placebo or an alternative sedative agent was evaluated on Overall incidence of ventricular arrhythmias (RR 0.35, 95% CI 0.16, 0.76). Dexmedetomidine significantly reduced the overall incidence of ventricular arrhythmias in adult patients during the perioperative cardiac surgery period (RR 0.35; 95% CI 0.16-0.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: